U.S. Food and Drug Administration staff reviewers said on Tuesday data demonstrating an immune response to Moderna's flu ...
The endorsement of an advisory committee positions Moderna to complete a dramatic turnaround for a shot the FDA declined to ...
The U.S. Food and Drug Administration's advisory panel is set to vote on whether the benefits of Moderna's flu vaccine ...
Ahead of a Thursday advisory panel meeting, agency scientists highlighted shortcomings in data accrued for a vaccine the FDA ...
During her presentation, Moderna’s Das said the company proposed a “modified regulatory framework” during the FDA meeting.
By Christy Santhosh and Mariam Sunny June 18 (Reuters) - Advisers to the U.S. FDA are meeting on Thursday to evaluate Moderna ...
The Food and Drug Administration (FDA) is getting ready to evaluate Moderna’s messenger RNA-based flu shot, MFLUSIVA, Fierce ...
Independent advisors for the Food and Drug Administration on Friday voted 9–0 in support of approving Moderna’s seasonal mRNA ...
CDC notes that the BA.2.86 (Pirola) variant may be more likely to break through existing immunity from previous vaccination or infection, highlighting the need for vaccination with an updated COVID-19 ...
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent ...
Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 5.1% in the afternoon session after the stock's positive momentum was extended as the company, along with partner Merck, presented positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results